Nuformix plc (LON:NFX – Get Free Report)’s stock price shot up 4.2% during mid-day trading on Wednesday . The stock traded as high as GBX 0.26 and last traded at GBX 0.25. 17,557,332 shares traded hands during trading, a decline of 54% from the average session volume of 38,040,898 shares. The stock had previously closed at GBX 0.24.
Nuformix Stock Performance
The firm has a market capitalization of £5.91 million, a PE ratio of -7.12 and a beta of 1.22. The firm’s 50-day moving average is GBX 0.26 and its 200 day moving average is GBX 0.22.
Nuformix (LON:NFX – Get Free Report) last posted its earnings results on Tuesday, January 27th. The company reported GBX (0.04) earnings per share for the quarter.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Read More
- Five stocks we like better than Nuformix
- Nvidia CEO Issues Bold Tesla Call
- Your Bank Account Is No Longer Safe
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
